FDA Approves Updated Drug Labeling for Capecitabine Tablets Under Project Renewal

FDA Approves Updated Drug Labeling for Capecitabine Tablets Under Project Renewal

header-info

On December 14, the US Food and Drug Administration (FDA) approved updated labeling for capecitabine tablets under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date.